Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

Abstract

BACKGROUND: Bipolar disorder is among the 10 most disabling medical conditions worldwide. While lithium has been used extensively for bipolar disorder since the 1970s, second-generation antipsychotics (SGAs) have supplanted lithium since 1998. To date, no randomized comparative-effectiveness study has compared lithium and any SGA. METHOD: Within the duration of the study (September 2010-September 2013), participants with bipolar I or II disorder (DSM-IV-TR) were randomized for 6 months to receive lithium (n = 240) or quetiapine (n = 242). Lithium and quetiapine were combined with other medications for bipolar disorder consistent with typical clinical practice (adjunctive personalized treatment [APT], excluding any SGA for the lithium + APT group and excluding lithium or any other SGA for the quetiapine + APT group). Coprimary outcome measures included Clinical Global Impressions-Efficacy Index (CGI-EI) and necessary clinical adjustments, which measured number of changes in adjunctive personalized treatment. Secondary measures included a full range of symptoms, cardiovascular risk, functioning, quality of life, suicidal ideation and behavior, and adverse events. RESULTS: Participants improved across all measures, and over 20% had a sustained response. Primary (CGI-EI, P = .59; necessary clinical adjustments, P = .15) and secondary outcome changes were not statistically significantly different between the 2 groups. For participants with greater manic/hypomanic symptoms, CGI-EI changes were significantly more favorable with quetiapine + APT (P = .02). Among those with anxiety, the lithium + APT group had fewer necessary clinical adjustments per month (P = .02). Lithium was better tolerated than quetiapine in terms of the burden of side effects frequency (P = .05), intensity (P = .01), and impairment (P = .01). CONCLUSIONS: Despite adequate power to detect clinically meaningful differences, we found outcomes with lithium + APT and quetiapine + APT were not significantly different across 6 months of treatment for bipolar disorder. TRIAL REGISTRATION: ClinicalTrials.gov identifier for the Bipolar CHOICE study: NCT01331304.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.14m09349

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

See all 81

Metadata

Authors
Nierenberg, A. A., McElroy, S. L., Friedman, E. S., Ketter, T. A., Shelton, R. C., Deckersbach, T., McInnis, M. G., Bowden, C. L., Tohen, M., Kocsis, J. H., Calabrese, J. R., Kinrys, G., Bobo, W. V., Singh, V., Kamali, M., Kemp, D., Brody, B., Reilly-Harrington, N. A., Sylvia, L. G., Shesler, L. W., Bernstein, E. E., Schoenfeld, D., Rabideau, D. J., Leon, A. C., Faraone, S., & Thase, M. E.
Affiliations
  • Harvard University (US)
  • University of Cincinnati (US)
  • University of Pittsburgh (US)
  • Stanford University (US)
  • University of Alabama at Birmingham (US)
  • University of Michigan (US)
  • The University of Texas at Austin (US)
  • University of New Mexico (US)
  • Cornell University (US)
  • Case Western Reserve University (US)
  • Mayo Clinic (US)
  • SUNY Upstate Medical University (US)
  • University of Pennsylvania (US)
Venue
The Journal of Clinical Psychiatry
Published
2016-01-27
Volume
77
Issue
01
Pages
90-99
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2278240795
Cited by
81
References
0
Citations by year
2026: 2 · 2025: 2 · 2024: 9 · 2023: 9 · 2022: 4 · 2021: 8 · 2020: 9 · 2019: 7 · 2018: 13 · 2017: 12 · 2016: 4
FWCI
10.66
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
Agency for Healthcare Research and Quality (R01HS019371, 1R01HS019371)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
bipolar disorder, lithium, quetiapine, atypical antipsychotics, comparative effectiveness, anxiety, drug tolerability, adverse effects, suicidal ideation, quality of life, cardiovascular risk
MeSH terms
Quetiapine Fumarate, Adult, Bipolar Disorder, Female, Humans, Lithium, Male, Middle Aged, Antipsychotic Agents, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder. https://app.cochat.ai/papers/10.4088/jcp.14m09349
The paper
Nierenberg, A. A., McElroy, S. L., Friedman, E. S., Ketter, T. A., Shelton, R. C., Deckersbach, T., McInnis, M. G., Bowden, C. L., Tohen, M., Kocsis, J. H., Calabrese, J. R., Kinrys, G., Bobo, W. V., Singh, V., Kamali, M., Kemp, D., Brody, B., Reilly-Harrington, N. A., Sylvia, L. G., . . . Thase, M. E. (2016). Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.14m09349

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.